Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758717 | 1.00 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL5191282 | 1.00 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL3758715 | 1.00 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL3758701 | 1.00 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL5191287 | 1.00 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL3770909 | 1.00 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL3758707 | 1.00 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL3758703 | 1.00 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL6899350 | 0.93 | ESR1 (0.33) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL3726007 | 0.93 | ESR1 (0.33) | ESR1PGRCHRM2ADORA3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1845078-B1 | PROCESS FOR PRODUCING LARGE CYCLIC KETONE AND INTERMEDIATE THEREFOR | TAKASAGO PERFUMERY CO LTD (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-7846701-B2 | Method for preparing optically active compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-7479574-B2 | Method of producing macrocyclic ketone, and intermediate thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-01-20 | — | — | US | disclosed |
| US-20070292925-A1 | Method for Preparing Optically Active Compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070287870-A1 | Method of Producing Macrocyclic Ketone, and Intermediate Thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1845078-A1 | PROCESS FOR PRODUCING LARGE CYCLIC KETONE AND INTERMEDIATE THEREFOR | Takasago International Corporation (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1813679-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE COMPOUND | Takasago International Corporation (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287870-A1 | Method of Producing Macrocyclic Ketone, and Intermediate Thereof | MSMO1, CYP17A1, DNMT1 | ESR1 1529/4885PGR 1476/4885CHRM2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.